Although data from prelicensure clinical trials revealed higher (not statistically significant) rates of KD among RotaTeq vaccines compared with placebo, our analysis of postmarketing data does not suggest an elevated risk of KD for RotaTeq or other US-licensed vaccines. Continued postmarketing monitoring for KD, including observational studies, are ongoing.
Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (https://www.pidj.com).
Pediatr Infect Dis J. 2009;28(11):944-947. © 2009 Lippincott Williams & Wilkins
Cite this: Kawasaki Disease After Vaccination: Reports to the Vaccine Adverse Event Reporting System 1990-2007 - Medscape - Nov 01, 2009.